17th Drug Discovery Strategic Summit
Medicilon is thrilled to exhibit in the 17th Drug Discovery Strategic Summit. The summit will take place from 23 to 24 October 2024 at Munich, Germany. Dr. Paul van Stralen, VP of Strategic Collaborations EMEA at Medicilon, will be available throughout the conference. We invite you to visit us at Medicilon Booth #6 to explore our services and capabilities.
Date: October 23-24, 2024
Location: Leonardo Hotel Munich Arabellapark, Munich, Germany
Medicilon Booth #6
About 17th DRUG DISCOVERY Strategic Summit
The 17th Drug Discovery Strategic Summit (DDSS) provides a forum for innovative ideas to meet actionable implementation. DDSS guides Drug Discoveries with strategic agility, allowing you to manage evolving areas with foresight and innovation. This Summit captures the core of panel discussions led by industry leaders, one-to-one meetings, an immersive display of cutting-edge solutions, innovative keynote presentations, dedicated networking hours, and insightful speakers and poster sessions. DDSS welcomes you to embark on a transformative journey that will equip you to lead the evolution of Drug Discoveries with precision and skill.
Medicilon Drug Discovery Services
With the rapid development of the global pharmaceutical market and the division of labor in the industry, the process of drug discovery and development is becoming increasingly refined. This makes specialized outsourcing an important strategic choice for pharmaceutical companies. In the early stages, companies often use FTE models for the synthesis of structural fragments and candidate compounds to accelerate the drug screening process. Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and we offer cooperation through both FFS and FTE models.
Medicilon Innovative R&D Technology Service Platforms
❖PROTAC
PROTACs offer a fast and reversible chemical knoc-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. As of the end of June 2024, Medicilon has successfully assisted in the clinical approval of 6 PROTAC drugs (2 approved by FDA and NMPA) and has 20+ PROTAC projects under development.
❖ADC
We specialize in Antibody-Drug Conjugates (ADCs), a revolutionary approach to cancer treatment. Our services encompass the entire ADC development process, including:
ADC Chemistry: Payload and linker R&D, antibody-drug conjugation
In Vitro Evaluation: Binding assays, internalization, cell cycle & apoptosis analysis, bystander effect studies
In Vivo Evaluation: Pharmacodynamics, pharmacokinetics, toxicology studies
Our team has successfully supported 28 IND approvals for ADC therapies, underscoring our leadership in this field.
❖Antibody
With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of April 2024, Medicilon has successfully assisted clients on the IND approval of 33 antibody drugs and has multiple antibody projects on going.
❖Nucleic Acid Drug
Medicilon nucleic acid drug R&D platform provides an integrated and comprehensive solution that covers drug discovery, CMC and preclinical research services. Oriented with a rigorous scientific approach, an open-minded teamwork spirit and state-of-the-art equipment, our integrated solution will help clients and partners to fulfil their research and development mission for cutting-edge and innovative nucleic acid drugs. Our service platforms include nucleic acid drug discovery, screening and preclinical research services of pharmacology, DMPK and toxicity study for both pharmaceutical companies and academic research institutions. Attributed by its fast and intuitive design of base sequences, the development of nucleic acid drugs is featured with simple materials, convenient preparation processes and affordable production costs, which will greatly shorten the drug development cycle, making it possible to customize individual treatment plans. Hence, it offers a feasible solution for rare diseases and other problems currently plagued.
❖Peptide
In the research and development of peptide drugs, the many characteristics of peptides have caused difficulties and challenges in the analysis process. In the analysis of peptide biotechnology drugs, Medicilon Biotechnology Drug Analysis Department flexibly uses ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology and other methods to support cutting-edge biology Drugs such as proteins, antibodies (monoclonal antibodies, bi- or multispecific antibodies, antibody fragments), ADCs, peptides, nucleic acids, vaccines and cell gene therapy and other drugs in the early development, preclinical and clinical stages of PK/TK/Immunogenicity (Total ADA& Nab)/Biomarker&Cytokine and other research evaluation.
❖mRNA Vaccine Bioanalysis Platform
Medicilon has provided comprehensive support and services for the safety and effectiveness evaluation of various new drugs and vaccines, specifically the research of LNP-mRNA drugs and vaccines, accumulating rich experience. Hence we establish the bioanalysis platform for mRNA vaccines.
❖Cell & Gene Therapy
Cell & Gene therapy has developed rapidly in recent years, providing the possibility of curing many difficult-to-treat cancers. With the rapid development of gene transduction and gene modification technology, delivery vector system, cell culture technology and other fields, gene therapy has made a breakthrough, provide a better solution, concept and idea for intractable diseases (especially rare genetic diseases). Medicilon has established a one-stop research platform for the preclinical R&D of cell & gene immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed multiple preclinical projects for clients worldwide.
❖AI R&D Innovation
As the first CRO stock on the Sci-tech Innovation Board, Medicilon is one of the companies that pay attention to AI technology in the industry at the beginning. Currently, Medicilon uses deep neural network machine learning technology to construct a BTK inhibitor drug design model. Medicilon also commits to establishing a molecular design and screening platform for BTK inhibitor drugs, launching “CRO+AI” to accelerate the development of new drugs.
#DDSS #drugdiscovery #newmolecule #target
Share：
Online registrationRelevant
news
marketing@medicilon.com
